Skip to content
DataLookout
Menu

NCT07548489

Phenobarbital for Agitated Delirium

StatusWithdrawn
PhasePhase 3
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗

  1. Stopped Withdrawn before enrolling Sponsor's reason: Not approved by IRB Show 4 more changesShow less
    • Enrollment target: estimated 150 to confirmed 0
    • Eligibility criteria expanded, about 5 words
    • Site contact updated
    • Publications: details revised at 1 of 1 entry
  2. Study First Submitted
  • Stopped: terminated, suspended or withdrawn

Endpoints

Primary

Provider Compliance
Timeframe: Six months

Secondary (3)

Hospital Length of Stay
ICU Length of Stay
Need for rescue medications

Arms and interventions

Phenobarbital TherapyExperimental

In alternating months, patients starting therapy for agitated delirium will be assigned to either a phenobarbital regimen or a conventional antipsychotic-based regimen. Patients assigned to Phenobarbital Therapy will receive this drug according to a validated protocol similar to that in use for patients with alcohol withdrawal. Additional "rescue" medications including dexmedetomidine will be available as needed.

Conventional TherapyActive comparator

In alternating months, patients starting therapy for agitated delirium will be assigned to either a phenobarbital regimen or a conventional antipsychotic-based regimen. Patients assigned to Conventional Therapy will receive antipsychotics as the primary medications for managing their agitation. Additional "rescue" medications including antipsychotics and dexmedetomidine will be available as needed.

Drugs: Phenobarbital, Conventional therapy group

Sites

1 site in 1 country

  • Duke Regional HospitalDurham, North Carolina, United States